NITRO-BID
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Jan 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
NITRO-BID by Sanofi is clinical pharmacology: the principal pharmacological action of nitroglycerin is relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins, especially the latter. Approved for angina pectoris due to coronary artery disease. First approved in 1982.
Drug data last refreshed 15h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NITRO-BID is a nitroglycerin ointment indicated for angina pectoris due to coronary artery disease. It works by relaxing vascular smooth muscle, dilating peripheral arteries and veins to reduce preload and afterload on the heart, and promoting coronary artery dilation. This small-molecule organic nitrate is delivered topically for sustained anti-anginal effect.
$0.001BPart D
LOE ApproachingDeclining
Mature product approaching loss of exclusivity with minimal claim volume; small brand team focused on legacy maintenance and generic transition management.
Mechanism of Action
CLINICAL PHARMACOLOGY: The principal pharmacological action of nitroglycerin is relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins, especially the latter. Dilatation of the veins promotes peripheral pooling of blood and decreases venous return to the…
Worked on NITRO-BID at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.